Investors shrugged as Illumina pressed its case for building on its longtime leadership in next-generation sequencing, ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors - making it the first antitissue-factor pathway inhibitor to be allowed for the ...

ETFs such as The Schwab US Dividend ETF can be useful, but a 'DIY' approach can help you outperform. Here are 3 of the best ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price ...

Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic ...

Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...

JPMorgan Chase, Wells Fargo and BlackRock reported strong quarterly results to kick off earnings season, but concerns linger ...

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 7. David ...

Advocate Group LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 3.8% during the third quarter, ...

Marcum Wealth LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 5.2% in the 3rd quarter, ...